Somatostatin analogs in the first-line therapy of well-differentiated thoracic neuroendocrine tumors: efficacy and control of carcinoid syndrome

Background. Data on the efficacy of somatostatin analogs (SSAs) in well-differentiated neuroendocrine tumors (NETs) of the lung and thymus remain limited. Carcinoid syndrome (CS) is one of the clinically significant manifestations of functional NET activity; however, its incidence, risk factors and control efficacy in thoracic NETs have not been sufficiently studied. Aim. To evaluate the efficacy of first-line SSA therapy in patients with well-differentiated thoracic NETs, examine the incidence of CS, serotonin level dynamics, and the impact of clinicopathological factors on CS development and progression-free survival (PFS). Materials and methods. This single-center, retrospective-prospective study included 44 patients with locally advanced unresectable or metastatic typical and atypical carcinoids of the lung and thymus. All patients received SSAs in the first-line therapy. The presence of CS was confirmed based on clinical presentation and/or elevated blood serotonin levels ≥500 ng/mL. Treatment efficacy was evaluated using RECIST 1.1 criteria. Univariate and multivariate analyses were performed to assess the impact of clinicopathological factors on CS development and PFS. Results. CS was reported in 13/44 (29.5%) patients. Full or partial symptom control was achieved in 76.9% of cases. Disease stabilization was recorded in 86.4% of patients, and the disease control rates at ≥6 and ≥12 months reached 79.5% and 72.7%, respectively. The median PFS was 24 months and decreased with higher Ki-67 levels (p=0.01). In the univariate analysis, factors associated with a high risk of progression included male sex, atypical carcinoid (G2+G3), Ki-67>10%, and liver metastases. In the multivariate analysis, only male sex emerged as an independent adverse factor affecting PFS. At a median follow-up of 35.5 months, the median overall survival (OS) was not reached. Conclusions. SSAs provide long-term control of both the disease and clinical manifestations of CS in patients with thoracic NETs. Elevated Ki-67 levels were associated with reduced PFS, while male sex was an independent adverse prognostic factor. These findings confirm the efficacy of first-line SSA therapy and warrant further investigation in a prospective cohort.

Authors

Institutions

Publication Details

Journal
Medical alphabet
Published
2026-11-17
DOI
https://doi.org/10.33667/2078-5631-2026-27-54-61
Primary Topic
Neuroendocrine Tumor Research Advances
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Somatostatin analogs in the first-line therapy of well-differentiated thoracic neuroendocrine tumors: efficacy and control of carcinoid syndrome

O. Yu. Martynova, Елена Владимировна Артамонова, Vera V. Delektorskaya, Екатерина Вадимовна Евдокимова et al.
Medical alphabet
Neuroendocrine Tumor Research Advances
article

Somatostatin analogs in the first-line therapy of well-differentiated thoracic neuroendocrine tumors: efficacy and control of carcinoid syndrome

O. Yu. Martynova, Елена Владимировна Артамонова, Vera V. Delektorskaya, Екатерина Вадимовна Евдокимова, А. А. Маркович, Ya. А. Zhulikov, M. A. Vorobyova
article en

Abstract

Background. Data on the efficacy of somatostatin analogs (SSAs) in well-differentiated neuroendocrine tumors (NETs) of the lung and thymus remain limited. Carcinoid syndrome (CS) is one of the clinically significant manifestations of functional NET activity; however, its incidence, risk factors and control efficacy in thoracic NETs have not been sufficiently studied. Aim. To evaluate the efficacy of first-line SSA therapy in patients with well-differentiated thoracic NETs, examine the incidence of CS, serotonin level dynamics, and the impact of clinicopathological factors on CS development and progression-free survival (PFS). Materials and methods. This single-center, retrospective-prospective study included 44 patients with locally advanced unresectable or metastatic typical and atypical carcinoids of the lung and thymus. All patients received SSAs in the first-line therapy. The presence of CS was confirmed based on clinical presentation and/or elevated blood serotonin levels ≥500 ng/mL. Treatment efficacy was evaluated using RECIST 1.1 criteria. Univariate and multivariate analyses were performed to assess the impact of clinicopathological factors on CS development and PFS. Results. CS was reported in 13/44 (29.5%) patients. Full or partial symptom control was achieved in 76.9% of cases. Disease stabilization was recorded in 86.4% of patients, and the disease control rates at ≥6 and ≥12 months reached 79.5% and 72.7%, respectively. The median PFS was 24 months and decreased with higher Ki-67 levels (p=0.01). In the univariate analysis, factors associated with a high risk of progression included male sex, atypical carcinoid (G2+G3), Ki-67>10%, and liver metastases. In the multivariate analysis, only male sex emerged as an independent adverse factor affecting PFS. At a median follow-up of 35.5 months, the median overall survival (OS) was not reached. Conclusions. SSAs provide long-term control of both the disease and clinical manifestations of CS in patients with thoracic NETs. Elevated Ki-67 levels were associated with reduced PFS, while male sex was an independent adverse prognostic factor. These findings confirm the efficacy of first-line SSA therapy and warrant further investigation in a prospective cohort.

Medical alphabet(27)
Pirogov Russian National Research Medical University (RU), Russian Cancer Research Center NN Blokhin (RU), Moscow Regional Scientific Research Clinical Institute. MF Vladimirsky (RU)
Neuroendocrine Tumor Research Advances
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon